


Renewal/Continuing Review from a Legacy Protocol


Notes: Complete Legacy first, if it hasn't been already. If you have any changes to make, submit a Modification **BEFORE** submitting the renewal.

After logging in, select **Human Ethics** from the Products drop-down.



Make sure **Researcher** is selected under the Role drop-down. Click on highlighted protocol, **New Submission** button.

Dashboard	Studies	Submissions	Tasks	Meetings	Reporting	More
IRB-2023-58	June 9th Test- Initial	Approved	Rocco Researcher	N/A	N/A	06-09-2023
IRB-2023-57	June 8th Test Initial	Approved	Rocco Researcher	N/A	N/A	06-08-2023



Click Edit

Unsubmitted

Initial

IRB-2023-76 - Test Settings

Edit

PDF

Delete

PI:
Tina Aubut

Current Analyst:
N/A

Decision:
N/A

Policy:
Post-2018 Rule

Review Type:
N/A

Review Board:
N/A

Meeting Date:
N/A

Cayuse is a smart form, you may not have to answer all these questions. It depends on your responses.

For the screenshots we clicked on all possibilities.

cayuse

Human Ethics

Role: Analyst

28

Prod

Dashboard

Studies

Submissions

Tasks

Meetings

Reporting

More

Renewal

Preview Only

Sections

Continuing Review

Continuing Review

Submit amendments/modifications separate from the continuing review.

* Request for More Time

Are you requesting more time for the project?

Yes

No

Provide a brief summary of activities to date:

B I U

Continuing Review

* IRB Oversight Arrangements

Indicate how IRB oversight is organized for this study. This should match what is in the latest approved version of this study (latest approved Modification or Initial approval).

Study involving 1 site where this site is the Reviewing IRB (IRB of Record)

Study involving more than 1 site where this site is the Reviewing IRB (IRB of Record) for other sites

Study involving more than 1 site where each site will conduct their own IRB review

Study involving more than 1 site where this site is Relying on an External IRB

Multi-site study (multiple US sites participating in a research study using the same protocol) where this site is the Reviewing IRB (IRB of Record) for all sites

Multi-site study (multiple US sites participating in a research study using the same protocol) where this site is Relying on an External IRB

Sections

Continuing Review

* Study & Subject Status

Check all that apply.

Study has not started or is on hold

Study enrollment is open; NO enrollment to date

Study enrollment is open and ongoing

Study enrollment is closed

Treatment and/or active follow-up continues

Long-term follow-up only (no intervention/interaction)

Remaining activities limited to data analysis

* Indicate what kind of data is in use:

Identifiable data is still in use (including coded data for which a link to the identifiable information is retained)

ONLY Coded data where BOTH are true:

ALL links to identifiable information have been destroyed

There is NO ability to link the data in use back to identifiable information

De-identified data ONLY

Continuing Review

Enrollment

For intervention/interaction studies or aims, Enrollment includes subjects who gave consent to participate, either in writing, orally, or by voluntary completion of a survey or participation in a focus group.

For data or specimen studies or aims, Enrollment includes subjects whose identifiable records/specimens have been reviewed.

* Total subjects enrolled to date at all sites

* Total subjects enrolled to date at this institution

* Total subjects enrolled at this institution since the last Renewal (or since Initial approval if this is the first Renewal)

Sections

Continuing Review

* Have there been any withdrawals at this institution during the this approval period?

NOTE: Includes subjects who consented but were determined ineligible, left voluntarily, or were withdrawn by study investigators.

☒ Yes

* Number of withdrawals this approval period

* Briefly explain the reason for each withdrawal.

B I U

Sections

Continuing Review

* Complaints

Have there been any subject complaints during this approval period?

Please address for this institution only, UNLESS we are the Reviewing IRB for other sites. In that case, consideration should include all sites (be sure to reference the site name).

☒ Yes

* Describe any subject complaints and if the subject withdrew from the study as a result.

B I U

Sections

Continuing Review

* Modifications

Have there been any changes to the study during this approval period that you have NOT already submitted as a Modification?

Please address for this institution only, UNLESS we are the Reviewing IRB for other sites. In that case, consideration should include all sites.

☒ Yes

Please create and submit a Modification with these changes immediately.

☐ No

Sections

Continuing Review

Reportable Events

This includes adverse events or protocol deviations that were required to promptly be submitted as an Incident per IRB Policy.

* Have any **Reportable Events** occurred during this approval period?

Please address for this institution only, UNLESS we are the Reviewing IRB for other sites. In that case, consideration should include all sites (be sure to reference the site name).

☒ Yes

* Please briefly describe the events.

B I U ↺ ☰ ☷ ↻

Continuing Review

☐ No

* Have all **Reportable Events** during this approval period already been submitted as Incidents?

Please address for this institution only, UNLESS we are the Reviewing IRB for other sites. In that case, consideration should include all sites.

☐ Yes

☒ No

Please create and submit Incident submissions for these reportable events immediately.

Sections

Continuing Review

Unreportable Events

This includes adverse events or protocol deviations that weren't required to promptly be submitted as an Incident per IRB Policy.

* Have any **Unreportable Events** occurred during this approval period?

☒ Yes

☐ No

* Provide a list of the unreportable events that occurred at this institution, including enough information to understand why the events were determined to be unreportable.

B I U ↺ ☰ ☷ ↻

* As applicable, provide a list of the unreportable events that occurred across the whole study at all sites, including enough information to understand why the events were determined to be unreportable.

This would ONLY be applicable for studies where we are the Reviewing IRB OR multi-site clinical trials (regardless of who is the IRB of Record).

B I U ↺ ☰ ☷ ↻

Unreportable Events Documentation

Attach any applicable documents for these unreportable events (e.g., event tracker).

ATTACH

Additional Documentation
If you have any additional documentation to provide for this Renewal, upload it here.

ATTACH

When done, click Complete Submission. Pop-ups will ask you to confirm.

The screenshot shows a sidebar menu on the left with three items: 'Attachments' with a checkmark icon, 'Routing' with a dropdown arrow and the text 'Send to PI for certification?', and 'COMPLETE SUBMISSION' with a right-pointing arrow. A pink oval highlights the 'Routing' and 'COMPLETE SUBMISSION' items. To the right, there is a text prompt 'Attach any consent, ass' and a grey 'ATTACH' button.

Certify submission: PI, CO-PI, and Faculty Sponsor (Advisor) **ALL** must certify each submission.

When all certification routing is done, it goes into the queue of an ORIO analyst for next steps.

The screenshot shows the 'Awaiting Certification' page for 'IRB-2023-16 - Test Research Project in Cayuse'. At the top right, there are 'Return' and 'Certify' buttons, with 'Certify' circled in red. Below this, a metadata section lists: PI: Tina Aubut, Current Analyst: N/A, Decision: N/A, Policy: Post-2018 Rule, and Required Tasks: N/A. It also lists Review Type: N/A, Review Board: N/A, and Meeting Date: N/A. A tabbed interface shows 'Approvals' as the active tab, with 'Task History' and 'Attachments' as options. At the bottom, a 'Research Team' table is displayed.

Name	Role	Result	Date
Tina Aubut	Principal Investigator	Pending Certification	